All that Glitas is Not Gold — Musings on Pharma Marketing & Type 2 Diabetes

The second-generation glitazones Avandia® (rosiglitazone) and Actos® (pioglitazone) — once touted as breakthrough drugs that could reduce cardiovascular mortality in patients with…

Read More →

Evidence-based Medicine, Type 2 Diabetes, & the Reign of Confusion

Evidence-based medicine (EBM) has gotten a lot of attention in recent years, as have questions pertaining to the importance of intensive glucose…

Read More →